Hikma launches foscarnet sodium injection
The product is indicated for the treatment of CMV retinitis in patients with AIDS.
Hikma is offering foscarnet sodium injection in a 6000 mg/250 ml bottle.
The product is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome. Combination therapy with foscarnet sodium and ganciclovir is indicated for patients who have relapsed after monotherapy with either drug.
Foscarnet sodium injection also is used for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients.
[Read more: Hikma intros Kloxxado]
Foscarnet sodium injection, 6000mg/250ml had a market value of approximately $19 million in the 12 months ending July 2024, per IQVIA.